KR101864719B1 - Composition for prevention and treatment of osteoporosis comprising the extract of medicinal herb mixture - Google Patents
Composition for prevention and treatment of osteoporosis comprising the extract of medicinal herb mixture Download PDFInfo
- Publication number
- KR101864719B1 KR101864719B1 KR1020170022634A KR20170022634A KR101864719B1 KR 101864719 B1 KR101864719 B1 KR 101864719B1 KR 1020170022634 A KR1020170022634 A KR 1020170022634A KR 20170022634 A KR20170022634 A KR 20170022634A KR 101864719 B1 KR101864719 B1 KR 101864719B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- extract
- parts
- health
- licorice
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 80
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 230000002265 prevention Effects 0.000 title claims abstract description 13
- 208000001132 Osteoporosis Diseases 0.000 title abstract description 34
- 238000011282 treatment Methods 0.000 title abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 26
- 208000020084 Bone disease Diseases 0.000 claims abstract description 16
- 235000018865 Angelica gigas Nutrition 0.000 claims abstract description 15
- 240000001810 Angelica gigas Species 0.000 claims abstract description 15
- 235000013402 health food Nutrition 0.000 claims abstract description 13
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 claims abstract description 8
- 240000008917 Glycyrrhiza uralensis Species 0.000 claims abstract description 8
- 244000274050 Platycodon grandiflorum Species 0.000 claims abstract description 7
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims abstract description 7
- 241001619454 Wolfiporia Species 0.000 claims abstract description 7
- 235000016278 Mentha canadensis Nutrition 0.000 claims abstract description 4
- 244000111489 Gardenia augusta Species 0.000 claims abstract 5
- 244000245214 Mentha canadensis Species 0.000 claims abstract 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 35
- 210000000988 bone and bone Anatomy 0.000 claims description 35
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 33
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 33
- 229940010454 licorice Drugs 0.000 claims description 33
- 230000036541 health Effects 0.000 claims description 29
- 241000202807 Glycyrrhiza Species 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 241001105098 Angelica keiskei Species 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 244000246386 Mentha pulegium Species 0.000 claims description 9
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 9
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 9
- 235000001050 hortel pimenta Nutrition 0.000 claims description 9
- 240000002045 Guettarda speciosa Species 0.000 claims description 7
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 7
- 241000092665 Atractylodes macrocephala Species 0.000 claims description 6
- 235000020737 peppermint extract Nutrition 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 230000037182 bone density Effects 0.000 claims description 4
- 229940069445 licorice extract Drugs 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 3
- 235000020710 ginseng extract Nutrition 0.000 claims 3
- 239000012046 mixed solvent Substances 0.000 claims 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims 1
- 241000411851 herbal medicine Species 0.000 abstract description 44
- 241000700159 Rattus Species 0.000 abstract description 15
- 230000011164 ossification Effects 0.000 abstract description 6
- 229940124597 therapeutic agent Drugs 0.000 abstract description 6
- 239000001841 zingiber officinale Substances 0.000 abstract description 6
- 235000006886 Zingiber officinale Nutrition 0.000 abstract description 5
- 244000273928 Zingiber officinale Species 0.000 abstract description 5
- 235000008397 ginger Nutrition 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 3
- 241000124501 Paeonia obovata var. japonica Species 0.000 abstract description 2
- 229940088597 hormone Drugs 0.000 abstract description 2
- 239000005556 hormone Substances 0.000 abstract description 2
- FBMORZZOJSDNRQ-GLQYFDAESA-N Atractylenolide III Chemical compound C=C([C@@H]1C2)CCC[C@]1(C)C[C@@]1(O)C2=C(C)C(=O)O1 FBMORZZOJSDNRQ-GLQYFDAESA-N 0.000 abstract 1
- 241000132011 Atractylodes lancea Species 0.000 abstract 1
- 235000018958 Gardenia augusta Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 244000303040 Glycyrrhiza glabra Species 0.000 description 18
- 235000005911 diet Nutrition 0.000 description 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 239000011575 calcium Substances 0.000 description 12
- 230000037213 diet Effects 0.000 description 12
- 239000013641 positive control Substances 0.000 description 12
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 11
- 229910052791 calcium Inorganic materials 0.000 description 11
- 238000000605 extraction Methods 0.000 description 10
- 229910052500 inorganic mineral Inorganic materials 0.000 description 10
- 239000011707 mineral Substances 0.000 description 10
- 210000000689 upper leg Anatomy 0.000 description 10
- 241000157835 Gardenia Species 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000012676 herbal extract Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 239000011574 phosphorus Substances 0.000 description 8
- 229910052698 phosphorus Inorganic materials 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 235000006679 Mentha X verticillata Nutrition 0.000 description 7
- 235000002899 Mentha suaveolens Nutrition 0.000 description 7
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 210000002997 osteoclast Anatomy 0.000 description 7
- 240000001972 Gardenia jasminoides Species 0.000 description 6
- 235000018823 dietary intake Nutrition 0.000 description 6
- 229910052732 germanium Inorganic materials 0.000 description 6
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 235000019786 weight gain Nutrition 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- -1 atractan A Chemical class 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 3
- 208000006386 Bone Resorption Diseases 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000736199 Paeonia Species 0.000 description 3
- 240000004371 Panax ginseng Species 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- 230000024279 bone resorption Effects 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000193755 Bacillus cereus Species 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241000193388 Bacillus thuringiensis Species 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000208671 Campanulaceae Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 235000017443 Hedysarum boreale Nutrition 0.000 description 2
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 102000000704 Interleukin-7 Human genes 0.000 description 2
- 241000695810 Lycoris x chejuensis Species 0.000 description 2
- 240000007707 Mentha arvensis Species 0.000 description 2
- 235000018978 Mentha arvensis Nutrition 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- 241000218201 Ranunculaceae Species 0.000 description 2
- 244000088415 Raphanus sativus Species 0.000 description 2
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 241000219873 Vicia Species 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 230000003474 anti-emetic effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 229940097012 bacillus thuringiensis Drugs 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229940106582 estrogenic substances Drugs 0.000 description 2
- JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940100994 interleukin-7 Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- GRWFGVWFFZKLTI-UHFFFAOYSA-N α-pinene Chemical compound CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 2
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
- XADJANKGURNTIA-YEXRKOARSA-N (2r)-2-[(3s,5r,10s,13r,14r,16r,17r)-3,16-dihydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,7,11,12,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-17-yl]-6-methyl-5-methylideneheptanoic acid Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CCC1=C2CC[C@]2(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(O)=O)[C@H](O)C[C@]21C XADJANKGURNTIA-YEXRKOARSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- ZTVSGQPHMUYCRS-SWLSCSKDSA-N (4as,8as)-3,8a-dimethyl-5-methylidene-4a,6,7,8-tetrahydro-4h-benzo[f][1]benzofuran-2-one Chemical compound C=C([C@@H]1C2)CCC[C@]1(C)C=C1C2=C(C)C(=O)O1 ZTVSGQPHMUYCRS-SWLSCSKDSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- OQYBLUDOOFOBPO-UHFFFAOYSA-N Asterolide Natural products C1C2C(=C)CCCC2(C)CC2C1=C(C)C(=O)O2 OQYBLUDOOFOBPO-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010068975 Bone atrophy Diseases 0.000 description 1
- 241000703121 Campanula rotundifolia Species 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010065420 Coronary artery dilatation Diseases 0.000 description 1
- PANKHBYNKQNAHN-JTBLXSOISA-N Crocetin Natural products OC(=O)C(\C)=C/C=C/C(/C)=C\C=C\C=C(\C)/C=C/C=C(/C)C(O)=O PANKHBYNKQNAHN-JTBLXSOISA-N 0.000 description 1
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 description 1
- SEBIKDIMAPSUBY-JAUCNNNOSA-N Crocin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C=CC=C(/C)C(=O)OC3OC(COC4OC(CO)C(O)C(O)C4O)C(O)C(O)C3O SEBIKDIMAPSUBY-JAUCNNNOSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- SKFGFFNYYMHHMG-UHFFFAOYSA-N Diacetyl-atractylodiol Natural products CC=CC#CC#CC=CCC(OC(C)=O)CCOC(C)=O SKFGFFNYYMHHMG-UHFFFAOYSA-N 0.000 description 1
- YJHVMPKSUPGGPZ-UHFFFAOYSA-N Dihydro-beta-eudesmol Natural products C1CC(C(C)(C)O)CC2C(C)CCCC21C YJHVMPKSUPGGPZ-UHFFFAOYSA-N 0.000 description 1
- UGMQOYZVOPASJF-UHFFFAOYSA-N Eburicoinsaeure Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC(=C)C(C)C)C(O)=O)CCC21C UGMQOYZVOPASJF-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 244000081616 Gardenia sp Species 0.000 description 1
- 235000006885 Gardenia sp Nutrition 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- AZKVWQKMDGGDSV-BCMRRPTOSA-N Genipin Chemical compound COC(=O)C1=CO[C@@H](O)[C@@H]2C(CO)=CC[C@H]12 AZKVWQKMDGGDSV-BCMRRPTOSA-N 0.000 description 1
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 description 1
- IBFYXTRXDNAPMM-FZEIBHLUSA-N Geniposide Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@H]2[C@@H]1CC=C2CO IBFYXTRXDNAPMM-FZEIBHLUSA-N 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- SFBODOKJTYAUCM-UHFFFAOYSA-N Ipriflavone Chemical compound C=1C(OC(C)C)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 SFBODOKJTYAUCM-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001106477 Paeoniaceae Species 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 208000031649 Postoperative Nausea and Vomiting Diseases 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 241001107098 Rubiaceae Species 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- 240000003705 Senecio vulgaris Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- XADJANKGURNTIA-UHFFFAOYSA-N Tumulosic acid Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC(=C)C(C)C)C(O)=O)C(O)CC21C XADJANKGURNTIA-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- SKFGFFNYYMHHMG-PMXBNEBOSA-N [(5e,11e)-3-acetyloxytrideca-5,11-dien-7,9-diynyl] acetate Chemical compound C\C=C\C#CC#C\C=C\CC(OC(C)=O)CCOC(C)=O SKFGFFNYYMHHMG-PMXBNEBOSA-N 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- IPZIYGAXCZTOMH-UHFFFAOYSA-N alpha-eudesmol Natural products CC1=CCCC2CCC(CC12)C(C)(C)O IPZIYGAXCZTOMH-UHFFFAOYSA-N 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002205 anti-dementic effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- VGLLGNISLBPZNL-RBUKDIBWSA-N arborescoside Natural products O=C(OC)C=1[C@@H]2C([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)=C(CO)CC2 VGLLGNISLBPZNL-RBUKDIBWSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- XFSVWZZZIUIYHP-UHFFFAOYSA-N beta-Eudesmol Natural products CC(C)(O)C1CCC2CCCC(=C)C2C1 XFSVWZZZIUIYHP-UHFFFAOYSA-N 0.000 description 1
- BOPIMTNSYWYZOC-VNHYZAJKSA-N beta-eudesmol Chemical compound C1CCC(=C)[C@@H]2C[C@H](C(C)(O)C)CC[C@]21C BOPIMTNSYWYZOC-VNHYZAJKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- PANKHBYNKQNAHN-JUMCEFIXSA-N carotenoid dicarboxylic acid Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)O)C=CC=C(/C)C(=O)O PANKHBYNKQNAHN-JUMCEFIXSA-N 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- PANKHBYNKQNAHN-MQQNZMFNSA-N crocetin Chemical compound OC(=O)C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O PANKHBYNKQNAHN-MQQNZMFNSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940091249 fluoride supplement Drugs 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- WWULHQLTPGKDAM-UHFFFAOYSA-N gamma-eudesmol Natural products CC(C)C1CC(O)C2(C)CCCC(=C2C1)C WWULHQLTPGKDAM-UHFFFAOYSA-N 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- AZKVWQKMDGGDSV-UHFFFAOYSA-N genipin Natural products COC(=O)C1=COC(O)C2C(CO)=CCC12 AZKVWQKMDGGDSV-UHFFFAOYSA-N 0.000 description 1
- 229940102465 ginger root Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 229960005431 ipriflavone Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 229930007503 menthone Natural products 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 208000002865 osteopetrosis Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229930184064 pinicolic acid Natural products 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100001055 skeletal defect Toxicity 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
- 229950004616 tribromoethanol Drugs 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/306—Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 당귀(Angelica gigas), 백작약(Paeoniae Radix Alba), 백출(Atractylodes macrocephala Koidzumi), 복령(Wolfiporia extensa), 치자(Gardeniae Fructus), 감초(Glycyrrhiza uralensis, Licorice), 길경(도라지(Platycodon grandiflorum A. DC.)의 뿌리), 건강(Zingiberis Siccatum Rhizoma) 및 박하(Mentha arvensis var. piperascens) 혼합추출물을 유효성분으로 함유하는 골질환 예방 또는 치료용 조성물에 관한 것이다.The invention Angelica (Angelica gigas), Paeonia japonica (Paeoniae Radix Alba), baekchul (Atractylodes macrocephala Koidzumi), Poria cocos (Wolfiporia Extensa , Gardeniae Fructus , Glycyrrhiza uralensis , Licorice), Geilyeong (root of Platycodon grandiflo rum A. DC.), health ( Zingiberis Siccatum Rhizoma) and mint ( Mentha I have arvensis . piperascens) as an active ingredient. The present invention also relates to a composition for preventing or treating bone diseases.
우리 몸을 이루고 있는 골조직은 골량(bone mass) 및 골격의 항상성(skeletal homeostasis)을 유지하기 위해 흡수와 형성이 끊임없이 일어나는 동적인 조직이다. 뼈를 파괴하고 신생시키는 데에는 조골세포와 파골세포가 작용하며, 조혈모세포에서 유래하는 파골세포는 오래된 뼈를 파괴 또는 재흡수(resorption) 과정을 통해 제거하고, 칼슘을 혈류로 방출하여 신체 기능을 유지하는데 관여하고, 뼈세포에서 생기는 조골세포는 새로운 뼈를 만들어 골격을 재건한다. 정상 성인에서는 골흡수 양과 골형성 양 사이에는 항상 균형이 유지되고 있으며, 조골세포와 파골세포 활성간의 불균형은 전체적인 골감소나 골증가를 발생시켜 골격의 이상으로 나타난다.The bone tissue that forms our body is a dynamic tissue that is constantly absorbed and formed to maintain bone mass and skeletal homeostasis. Osteoclasts and osteoclasts act to destroy and initiate bone destruction. Osteoclast-derived osteoclasts remove old bone through destruction or resorption, releasing calcium into the blood stream to maintain body function , And the osteoblast cells that form in the bone cells make new bones and rebuild the skeleton. In normal adults, there is always a balance between the amount of bone resorption and the amount of bone formation, and the imbalance between osteoblast and osteoclast activity results in a total osteoclast or osteogenesis, resulting in skeletal abnormalities.
청소년기에는 뼈의 형성이 뼈의 파괴보다 활발하게 일어나고, 성인이 되면 형성과 파괴가 균형을 이루면서 정상적인 뼈의 리모델링이 일어나게 되지만 노년기가 되게 되면 뼈의 형성보다 뼈의 파괴가 더 활발하게 일어나게 되어 병이 생기는 원인이 된다. 이처럼 골흡수 양과 골형성 양 사이의 균형을 이루지 못하게 되면 류마티스 관절염(rheumatoid arthritis), 골다공증(osteoporosis), 조골세포의 활동이 너무 활발하여 뼈의 밀도가 높아지는 골석화증(osteopetrosis) 및 변형성 뼈염이라고 불리는 파제트병(Paget's disease), 골연화증(osteomalacia), 골감소증(osteopenia), 골위축(bone atrophy), 골관절염(osteoarthritis)과 같은 골질환이 생기게 된다.In adolescence, bone formation occurs more actively than bone destruction, and when adults are formed, normal bone remodeling occurs as the balance between formation and destruction becomes. However, when it becomes old, bone destruction becomes more active than bone formation, It causes it. Such a failure to achieve a balance between the amount of bone resorption and the amount of bone formation may be caused by rheumatoid arthritis, osteoporosis, osteopetrosis, which is caused by excessive activity of osteoblasts and bone density, Bone diseases such as Paget's disease, osteomalacia, osteopenia, bone atrophy and osteoarthritis are caused.
구체적으로 골다공증(osteoporosis)은 골(骨)조직의 석회가 감소되어 뼈의 치밀질이 엷어지고 그로 인해 골수강(骨髓腔)이 넓어지고, 증세가 진전됨에 따라 뼈가 약해지기 때문에 작은 충격에도 골절되기 쉽다. 골량은 유전적 요인, 영양 섭취, 호르몬의 변화, 운동 및 생활 습관의 차이 등 여러 가지 요인들에 의해 영향을 받으며, 골다공증의 원인으로는 노령, 운동 부족, 저체중, 흡연, 저칼슘 식이, 폐경, 난소 절제 등이 알려져 있다. 한편 개인차는 있지만 백인보다는 흑인이 골 재흡수 수준(bone resorption level)이 낮아 골량이 더 높으며, 대개 골량은 14 ~ 18세에 가장 높고 노후에는 1년에 약 1 %씩 감소한다. 특히 여성의 경우 30세 이후부터 골 감소가 지속적으로 진행되며, 폐경기에 이르면 호르몬 변화에 의해 골 감소가 급격히 진행된다. 즉, 폐경기에 이르면 에스트로젠 농도가 급속히 감소하는데, 이때 IL-7(interleukin-7)에 의한 것처럼 B-임파구(B-lymphocyte)가 다량 생성되어 골수(bone marrow)에 B 세포 전구체(pre-B cell)가 축적되고 이로 인해 IL-6의 양이 증가하여 파골 세포의 활성을 증가시키므로 결국 골량이 감소하게 된다. 이와 같이 골다공증은 정도에 차이는 있으나 노년층, 특히 폐경기 이후의 여성에게 있어서는 피할 수 없는 증상으로, 선진국에서는 인구가 노령화됨에 따라 골다공증 및 그 치료제에 대한 관심이 점차 증가되고 있다. 또한, 전 세계적으로 골질환 치료와 관련되어 약 1,300억 달러의 시장이 형성되어 있으며 앞으로 더 증가할 것으로 예상되기 때문에, 세계적인 각 연구 기관과 제약회사에서는 골질환 치료제 개발에 많은 투자를 하고 있다.Specifically, osteoporosis is caused by a decrease in the lime of the bone tissue, a decrease in the density of the bone, a widening of the bone cavity, and progress of the symptoms. As a result, the bone is weakened. . The bone mass is affected by various factors such as genetic factors, nutritional intake, hormonal changes, exercise and lifestyle differences, and the causes of osteoporosis include age, lack of exercise, low birth weight, smoking, low calcium diet, Ovariectomy and the like are known. Although there are individual differences, blacks have a lower bone resorption level than blacks, and bone mass is higher. Usually, bone mass is highest at 14-18 years old and decreases about 1% per year at old age. Especially in women, bone reduction continues after 30 years of age, and bone turnover is rapidly progressed by hormonal changes in menopause. In the postmenopausal period, the concentration of estrogen rapidly decreases, and a large amount of B-lymphocyte is produced as in the case of IL-7 (interleukin-7), and the B-cell precursor ) Accumulates and increases the amount of IL-6, thereby increasing the activity of osteoclast, resulting in a decrease in bone mass. Thus, osteoporosis is an unavoidable symptom for elderly people, especially postmenopausal women. In the developed countries, as population ages, interest in osteoporosis and its therapeutic agents is gradually increasing. In addition, there is a market of about $ 130 billion related to the treatment of bone disease worldwide and is expected to increase further in the future, so that each research institute and pharmaceutical company in the world invests heavily in the development of bone disease treatments.
현재 골다공증 치료제로 사용되고 있는 물질로는 에스트로젠(estrogen), 앤드로제닉 아나볼릭 스테로이드(androgenic anabolic steroid), 칼슘 제제, 인산염, 불소 제제, 이프리플라본(Ipriflavone), 비타민 D3 등이 있다. 또한 1995년 미국 머크사에서는 아미노비스포스포네이트(aminobisphosphonate)를, 1997년 미국 릴리사(Lilly Co.)에서는 선택적인 에스트로젠 수용체 조절기(selective estrogen receptor modulator, SERM)로써 역할하는 라록시펜(raloxifene)을 골다공증 치료제로 개발한 바 있다.Currently, estrogen, androgenic anabolic steroids, calcium, phosphate, fluoride, ipriflavone, and vitamin D3 are used in osteoporosis treatment. In addition, aminobisphosphonate was used in Merck, USA in 1995, and raloxifene, a selective estrogen receptor modulator (SERM) in the US Lilly Co. in 1997, .
당귀(Angelica gigas)는 산형과(Umbeniferae)로 뿌리를 채취한 후, 잔뿌리를 잘라 버리고 햇볕에 말려 사용하며 특이한 향기가 있다. 한방에서는 빈혈증, 부인병, 임산부의 산후 회복에 주로 쓰이며 심한 기침, 부스럼 등에도 효과가 있다고 알려져 있다. 또한, 당귀는 자궁을 튼튼하게 할 뿐 아니라 생리를 조절하여 피 찌꺼기 등 노폐물을 빼내는 역할을 하며 냉증, 혈색 불량, 산전 산후의 회복과 피가 부족할 때 보혈작용도 하고 혈액정화작용 및 장의 운동을 활발하게 해주므로 손, 발이 찬 증상을 개선시킬 수 있다. Angelica gigas is rooted in Umbeniferae, then cuts off the roots, uses them in the sun, and has a peculiar smell. It is known to be effective in the treatment of anemia, women's diseases, pregnant women, postpartum recovery, severe cough and swelling. In addition, it not only strengthens the uterus but also regulates the physiology to extract the waste materials such as the blood residue. It also helps the blood circulation, deficiency of blood color, restoration of prenatal and postnatal blood, blood purification and movement of the intestines So that your hands and feet can improve your cold symptoms.
작약(Paeoniaceae)은 미나리아재비목, 미나리아재비과, 목단속(paeonia)의 여러해살이풀로, 백작약(Paeoniae Radix Alba)과 적작약(Paeoniae Radix Rubra)이 있다. 백작약과 적작약은 껍질의 유무로 결정하고 있으며, 껍질이 있는 것을 적작약, 껍질을 벗겨낸 것을 백작약이라고 한다(Altern. Med. Rev., 6(5), pp495-499, 2001). 백작약은 적작약과 더불어 위, 장의 평활근 및 자궁평활근에 대해 수축억제효과, 관동맥 확장 효과 및 혈관질환에 대해 죽상경화증 방지, 혈압강하 및 혈류 개선의 효과가 있다. 작약추출물의 이러한 효과는 항산화효과(Ohsugi M et al., J. Ethnopharmacol., 67, pp111-119, 1999), 혈소판응집억제효과(Lin HC et al., Planta Med , 65, pp595-599, 1999), 항혈전효과(Ishida H et al.,Chem. Pharm. Bull, 35(2), pp849-852, 1987), 고지혈증 방지(Yang HO et al., Fitoterapia, 75(1), pp45-49, 2004) 및 고지혈증으로부터 혈관내피세포 보호기능(Goto H et al., Phytother. Res,13(6), pp526-528, 1999) 등으로부터 오는 것으로 보여진다. 또한, 작약의 구성성분 중의 일부인 글리코시드(glycoside)가 뇌경색의 치료에 효과가 있는 것으로 보고되었는데(Yang J et al., Zhong Yao Cai, 23(2), pp95-97, 2000), 이는 작약의 구성성분인 페오니플로린(paeoniflorin)이 신경세포에 대해 보호 효과가 있기 때문인 것으로 보인다(Zhang GQ et al., Acta Pharmacol. Sin., 24(12), pp1248-1252, 2003). Paeoniaceae is a perennial plant of the family Ranunculaceae, Ranunculaceae, and paeonia . There are Paeoniae Radix Alba and Paeoniae Radix Rubra. Rev., 6 (5), pp. 495-499, 2001), and the peeled and peeled peel is called the peel. Veterinary medicines have the effect of suppressing atherosclerosis, decreasing blood pressure and improving blood flow, as well as anti-constipation effect, coronary artery dilatation effect and vascular disease in stomach, intestinal smooth muscle and uterine smooth muscle. This effect of the peony extract was confirmed by the antioxidant effect (Ohsugi M et al., J. Ethnopharmacol., 67, pp 111-119, 1999), platelet aggregation inhibitory effect (Lin HC et al., Planta Med, 65, pp 595-599, 1999 (Yang Ho et al., Fitoterapia, 75 (1), pp 45-49, 1987), anti-thrombotic effect (Ishida H et al., Chem. Pharm. Bull, 2004) and vascular endothelial cell protection from hyperlipidemia (Goto H et al., Phytother. Res., 13 (6), pp 526-528, 1999). In addition, it has been reported that glycoside, which is one of the constituents of peonies, is effective in the treatment of cerebral infarction (Yang J et al., Zhong Yao Cai, 23 (2), pp95-97, (Zhang GQ et al., Acta Pharmacol. Sin., 24 (12), pp. 1248-1252, 2003), as the constituent paeoniflorin protects against neurons.
백출(Atractylodes macrocephala Koidzumi)은 국화과에 속하는 다년생초인 삽주의 뿌리로 소화기능과 이뇨작용을 도와주는 약재로써 고유의 향을 갖고 있다. 성분은 정유성분과 비타민 A, D를 함유하고 있다. 정유성분 중에 세리나는 항염효과[Chem. Pham. Bull.,27(12),2965,1979], 항치매효과(일본공개 특허 JP09094452) 등이 연구 보고되어 있고 피부미백제(한국공개특허 1999-0085303)로 우수한 효과를 가지고 있다고 보고되어 있다. 백출은 혈압강하 및 촉진효과 외에 항세균, 항진균성과 더불어 건위, 진정, 진통효과가 있다. 백출에는 애트랙티론(atractyion), 애트랙티레노라이드 Ⅰ, Ⅱ, Ⅲ(atractylenolide Ⅰ, Ⅱ, Ⅲ), 디아세틸-애트락틸오디올(diacetyl-atractylodiol), 푸르푸랄(furfural), 베터-유데스몰(β-eudesmol) 기타 다당류인 애트랙탄(atractan) A, B, C 등 혈당강하작용이 있는 물질이 함유되어있다. Atractylodes macrocephala Koidzumi) is a perennial herb that belongs to Asteraceae and has a unique fragrance as a medicinal substance that helps digestion and diuretic action. Ingredients contain essential oils and vitamins A and D. Serine in the essential oil component has anti-inflammatory effect [Chem. Pham. Bull., 27 (12), 2965, 1979], anti-dementia effect (JP09094452) and the like have been reported and skin whitening agents (Korea Patent Publication 1999-0085303) have been reported to have excellent effects. In addition to the blood pressure lowering and promoting effect, Bacillus has anti-bacterial, anti-bacterial effect, and has a dryness, soothing and analgesic effect. The extracts may contain atractylion, atractylenolide I, II, III, diacetyl-atractylodiol, furfural, beta- Desmol (β-eudesmol) Other polysaccharides such as atractan A, B, and C have hypoglycemic substances.
복령(茯)(Wolfiporia extensa)은 분류학적으로 진정담자균강, 동담자균아강(모균아강), 민주름버섯목, 구멍장이버섯과에 속한다. 주로 소나무에서 사물기생을 하지만 살아있는 소나무의 뿌리와 연결되어 활물기생을 하기도 하는 갈색 부후균으로 담자균류에 속하는 균류의 일종이다. 균사는 백색으로 분지하면서 계속 생장하다가 균사들끼리 서로 엉기기 시작하고, 온도 습도 등 알맞은 환경조건이 지속되면 내구체인 단단한 덩어리 형태의 균핵이 형성된다. 이것을 우리는 복령이라 하며, 내부의 색깔에 따라서 백색이면 백복령, 담홍색이면 적복령이라 한다. 복령의 주요 성분은 복령산(Parchymic acid, C33H52O5), 송령산(Pinicolic acid, C30H18O30), 송령신산(3β-Hyderoxy-lanosta-7.9(11), 24-Trien-21-Oic aicd와 Tumulosic acid(C31H50O) Ebricoic acid(C31H50O3) 등이 함유되어 있으며 양질의 복령에는 그 중에서도 가장 중요한 Pachyman 함량이 93 %에 이르고 있다. 또한, 복령은 심신의 보양 및 안정, 이뇨 증진. 정신안정 등의 작용이 있는 것으로 알려져 있고 건망증, 불면증, 만성위염, 신체 허약자 등에도 치료효과가 높은 것으로 알려져 있다. Wolfiporia (茯) extensa ) belongs to the genus Staphylococcus aureus, the genus Bacillus subtilis (bacillus subtilis) It is a kind of fungus belonging to bacillus, which is a brown rot fungus which is mainly parasitized by pine trees but is linked to the roots of living pine trees. Mycelium grows while branching to white and hyphae begin to grow together. When the proper environmental conditions such as temperature and humidity are maintained, a hard lump-shaped sclerotia is formed. We call this the Bokryeong, and if it is white according to the color of the inside, it is called Baekbokgyeong, and if it is pale pink, it is called Baekbokryeong. The main constituents of the gyeongryeong were selected from the group consisting of Parchymic acid (C33H52O5), Pinicolic acid (C30H18O30), 3β-Hyderoxy-lanosta- 7.9 (11), 24-Trien-21-Oic aicd and Tumulosic acid ), Ebricoic acid (C31H50O3), etc. The most important among them is Pachyman content of 93%. In addition, Byeongryeong is known to have the functions of mind and body, It is known that amnesia, insomnia, chronic gastritis, and physical weakness have a high therapeutic effect.
치자(Gardeniae Fructus)란 꼭두서니과(Rubiaceae)에 속하는 식물로서 주성분은 크로신(Crocin), 크로세틴(Crocetin), 가르도닌(Gardonin), 제니핀(Genipin), 제니포사이드(Geniposide) 등이 있으며, 노란 색소에는 알파크로찐, 크산찔레틴, 프소랄렌, 파우쩨다놀메틸, 에스테르 등의 성분이 있다. 치자는 예로부터 민간요법에서는 타박상, 상처에 이용되며, 동의보감에서는 열대림, 피멎이약, 소염, 토혈, 각혈, 황달에 효과가 있다는 개시가 있었다. Gardeniae Fructus is a plant belonging to the family Rubiaceae. Its main components are Crocin, Crocetin, Gardonin, Genipin and Geniposide. Alpha-crochine, xanthan gum, xylenes, xanthanole methyl, and esters. Gardenia has been used in folk remedies for bruises and scratches for a long time, and Dongbangbo has been proved to be effective for tropical forest, pesotanic acid, anti-inflammation, blood, blood and jaundice.
감초(Glycyrrhiza uralensis, Licorice)는 시베리아 동부와 중국 동북부가 원산인 콩과의 다년초로서 뿌리가 달기 때문에 감초라고 하며 약방의 감초라고 할 정도로 한방약에 거의 포함되는 중요한 생약으로 부작용에 대한 우려가 적다. 감초(Glycyrrhiza)는 장미목 콩과의 약용식물로서, 감초는 유효성분으로 그라이시리진(Glycyrrhizin)이 알려져 있으며 그 외의 성분이 위액분비 억제 및 궤양수복 작용도 하는 것으로 인정되고 있다. 또한 감초 엑기스에는 에스트로겐 양작용, 진해작용, 항염증작용, 항알러지작용, 해독작용, 고지혈증 개선작용 등이 있는 것으로 밝혀져 있다.Licorice ( Glycyrrhiza uralensis , Licorice) is a perennial plant of eastern Siberia and the northeastern part of China. It is called licorice because its roots are rooted. It is an important medicinal herb that is almost contained in Chinese medicine. Licorice ( Glycyrrhiza ) is a medicinal plant with rosemary beans. Licorice is known to be an effective ingredient, glycyrrhizin, and other ingredients have been shown to inhibit gastric juice secretion and repair ulcer. In addition, licorice extract has been found to have estrogen action, anti-inflammatory action, anti-inflammatory action, anti-allergic action, detoxification action, and hyperlipidemia-improving action.
길경은 초롱꽃과(Campanulaceae)의 식물인 도라지(Platycodon grandiflorum A. DC.)의 뿌리로, 길경은 주로 거담, 진해작용, 기침 및 기관지염의 치료제로 사용되어왔으며, NF-kB와 NO assay를 통한 항염증 효과, 항암효과, 통증 완화효과, 소화효소 분비억제효과, 콜레스테롤 대사 개선효과가 있는 것으로 알려져 있다.Gilgyeong is a campanulaceae plants (Campanulaceae) Bellflower (Platycodon grandiflorum A. DC.), Gakgyeong has been mainly used for the treatment of gadam, Jinhae, cough and bronchitis. It has anti-inflammatory, anti-cancer effect, pain relieving effect, digestive enzyme secretion through NF- Inhibitory effect, and cholesterol metabolism.
건강(Zingiberis Siccatum Rhizoma)은 생강의 뿌리줄기를 껍질째 말린 건조품을 말하며, 건강의 물 추출액은 타액에 의한 전분 소화력의 촉진 및 황산동에 의한 구토를 억제하고, 건강 가루는 멀미, 수술 후나 임신부의 구토에 효과적이며, 이러한 항구토 작용은 중추신경계에 대한 작용보다는 위장관에 직접 작용하여 나타나는 것으로 알려져 있다(생약학교재편찬위원회, 생약학, 동명사, 2006). 이외에도 항당뇨(Akhani SP et el., Antidiabetic activity of Zingiber officinale in streptozotocin-induced type I diabetic rats, J. Pharm. Pharmacol, 56(1),pp.101-105, 2004) 및 항불안제(Vishwakarma SL et el., Anxiolytic and antiemetic activity of Zingiber officinale, Phytother. Res., 16(7),pp.621-626, 2002) 등의 작용도 있는 것으로 연구결과에서 보고되었다.Health ( Zingiberis Siccatum Rhizoma) refers to the dried root of ginger root, the water extract of health suppresses the stimulation of starch digestion by saliva and vomiting due to copper sulphate, and the health powder is effective for nausea, postoperative nausea and vomiting of pregnant woman , And it is known that this septic effect acts directly on the gastrointestinal tract rather than on the action of the central nervous system (Pharmacodynamic Textbook Compilation Committee, Pharmacology, Dongmyung, 2006). In addition, anti-diabetic agents (Vishwakarma SL et el., Et al., Antidiabetic activity of Zingiber officinale in streptozotocin-induced type I diabetic rats, J. Pharm. Pharmacol., 56 (1), pp. , Anxiolytic and antiemetic activity of Zingiber officinale, Phytother. Res., 16 (7), pp.621-626, 2002).
박하(Mentha arvensis var. piperascens)는 쌍떡잎식물 통화식물목 꿀풀과의 여러해살이 숙근초로서, 주요성분이 알파-피넨(alpha-pinene(+, -)), 아니스알데히드(anisaldehyde), 다우코스테롤(Daucosterol), 유제놀(Eugenol), 리날롤(Linalool), 멘톤(Menthone), (+)-네오멘톨((+)-Neomenthol) 등이고, 피부의 점막과 혈관을 수축하는 작용, 신경 말초를 마비시키는 작용, 통증을 멎게 하는 작용, 소양감을 멈추게 하는 작용이 있어서 피부에 특유의 청량감을 주어 피부병을 개선하고 피부 진정작용과 항산화효과가 있다. Mentha I have arvensis . piperascens) is a perennial herbaceous perennial plant of the dicotyledonous plant with a monocotyledonous plant. Its main components are alpha-pinene (+, -), anisaldehyde, daucosterol, eugenol ), Linalool, Menthone, (+) - neomenthol ((+) - Neomenthol), and the action of contracting the mucous membrane and blood vessels of the skin, paralyzing the peripheral nerve, , It has the effect of stopping the feeling of pungency, giving skin a unique feeling of refreshing to improve skin diseases, and has a sedative and antioxidant effect on the skin.
생약재 추출물을 포함하는 골다공증 예방 및 치료용 조성물에 관한 특허로 대한민국 공개특허 제 2005-0072625호에는 숙지황, 두충, 우슬, 당귀, 구기자, 육계(肉桂), 속단, 감초, 산사자, 토사자, 상지, 백복령, 인삼, 녹용, 구판주자, 사인 등을 포함하는 골다공증 개선 및 예방용 조성물이 개시되어 있고, 대한한방부인과학회지 21권 1호 2008년호에는 가미소요산(加味逍遙散)이 난소적출로 유발된 흰 쥐의 골다공증에 미치는 영향을 개시하고 있다. 다만 상기 문헌에 개시된 혼합 조성물은 일부 골다공증 치료효과를 가지나 현저한 골다공증 치료효과를 나타내지 못하므로 유의적인 골다공증 치료효과를 갖는 조성물의 개발이 시급한 실정이다. Korean Patent Publication No. 2005-0072625 discloses a composition for preventing and treating osteoporosis comprising a herbal medicine extract and a composition for preventing and treating osteoporosis. A composition for improving and preventing osteoporosis, which comprises ginseng, antler, antiperspirant, sine, and the like, is disclosed. In the Korean Oriental gynecological Society, Vol. 21, No. 1, 2008, there is disclosed a composition for ovariectomized white rats On osteoporosis of < / RTI > However, since the mixed composition disclosed in the above document has some osteoporosis treatment effect but does not exhibit a remarkable effect of treating osteoporosis, it is urgent to develop a composition having a significant osteoporosis treatment effect.
이에, 본 발명자들은 인체에 독성이 없는 천연물을 대상으로 현저한 골질환 치료제를 개발하기 위해 노력한 결과, 당귀, 백작약, 백출, 복령, 치자, 감초, 길경, 건강 및 박하의 혼합 생약재 추출물이 난소를 적출한 흰쥐모델에서 Bone mineral density를 현저하게 증가시키므로 골다공증을 예방하고 치료하는데 효과적으로 사용될 수 있음을 밝힘으로써 본 발명을 완성하였다.As a result, the present inventors have made efforts to develop a therapeutic agent for bone disease which is not toxic to the human body. As a result, it has been found that the herbal extract of Angelica gigas, Pseudomonas aeruginosa, The present invention has been completed based on the finding that bone mineral density is significantly increased in a rat model and thus can be effectively used for preventing and treating osteoporosis.
종래 골다공증 치료제는 대부분 에스트로겐 계통의 물질로서, 에스트로겐 계통의 물질은 장기 투여할 경우 암, 담석, 혈전증 등의 부작용이 나타난다. 그러나 골다공증은 약물의 단기 투여만으로는 치료할 수 없으며 약물의 장기 투여가 필수적이다. 따라서, 약물을 장기 투여할 때에도 상기와 같은 부작용이 없고 에스트로겐을 대체할 수 있을 만큼 우수한 약효를 갖는 새로운 물질이 필요하다. 따라서 본 발명의 목적은 장기간 투여했을 경우에도 부작용이 없고 탁월한 골다공증 예방 및 치료 효과를 발휘할 수 있는 생약 추출물을 이용한 골다공증 예방 및 치료용 약학 조성물 또는 건강식품을 제공하기 위한 것이다. Conventional osteoporosis medicines are mostly estrogenic substances, and estrogenic substances have side effects such as cancer, gallstones, and thrombosis when administered over a long period of time. However, osteoporosis can not be treated by only short-term administration of the drug, and long-term administration of the drug is essential. Therefore, even when the drug is administered for a long period of time, there is a need for a new substance that has the above-mentioned side effects and has a medicinal effect sufficiently high enough to replace estrogen. Accordingly, an object of the present invention is to provide a pharmaceutical composition or a health food for prevention and treatment of osteoporosis using a herbal medicine extract which has no side effects even when administered for a long period of time and can exert excellent osteoporosis prevention and therapeutic effect.
상기 목적을 달성하기 위하여, 본 발명은 당귀(Angelica gigas), 백작약(Paeoniae Radix Alba), 백출(Atractylodes macrocephala Koidzumi) 및 복령(Wolfiporia extensa) 추출물을 포함하고, 치자(Gardeniae Fructus), 감초(Glycyrrhiza uralensis, Licorice), 길경(도라지(Platycodon grandiflorum A. DC.)의 뿌리), 건강(Zingiberis Siccatum Rhizoma) 및 박하(Mentha arvensis var. piperascens)로 구성된 군으로부터 선택되는 어느 하나 이상의 추출물을 추가적으로 함유하는 골질환 예방 또는 치료용 약학적 조성물을 제공한다.In order to achieve the above object, the present invention provides a method for producing Angelica gigas , Paeoniae Radix Alba, Atractylodes macrocephala Koidzumi and Wolfiporia extensa extract, and Gardeniae Fructus , Licorice ( Glycyrrhiza uralensis , Licorice), Gyungyong ( Platycodon grandiflorum A. DC.)), Health ( Zingiberis Siccatum Rhizoma) and mint ( Mentha I have arvensis . piperascens). The present invention also provides a pharmaceutical composition for preventing or treating bone diseases.
상기 목적을 달성하기 위하여, 본 발명은 당귀, 백작약, 백출 및 복령 추출물을 포함하고, 치자, 감초, 길경, 건강 및 박하로 구성된 군으로부터 선택되는 어느 하나 이상의 추출물을 추가적으로 함유하는 골질환 예방 또는 개선용 건강식품을 제공한다.In order to achieve the above object, the present invention provides a method for preventing or ameliorating osteoporosis, which comprises an extract of Angelica keiskei, Veterinary medicine, Health food.
본 발명의 당귀(Angelica gigas), 백작약(Paeoniae Radix Alba), 백출(Atractylodes macrocephala Koidzumi) 및 복령(Wolfiporia extensa) 추출물을 포함하고, 치자(Gardeniae Fructus), 감초(Glycyrrhiza uralensis, Licorice), 길경(도라지(Platycodon grandiflorum A. DC.)의 뿌리), 건강(Zingiberis Siccatum Rhizoma) 및 박하(Mentha arvensis var. piperascens)로 구성된 군으로부터 선택되는 어느 하나 이상의 추출물을 추가적으로 함유하는 조성물은 체내 안전하고 뼈의 무게와 길이를 증가시키고 Bone mineral density를 증가시키는 효과를 나타내므로 골질환 예방 및 치료용 조성물로 사용될 수 있으며, 부작용이 존재하는 기존 골질환 예방 및 치료제의 대체 물질로 사용될 수 있을 뿐 아니라 건강식품으로도 활용 가능하다.The Angelica gigas , Paeoniae Radix Alba, Atractylodes macrocephala Koidzumi and Wolfiporia extensa extract, and Gardeniae Fructus ), licorice ( Glycyrrhiza uralensis , Licorice, Root of Platycodon grandiflorum A. DC), Health ( Zingiberis Siccatum Rhizoma) and mint ( Mentha arvensis there is. piperascens) is safe in the body, increases the weight and length of bones, increases bone mineral density, and can be used as a composition for prevention and treatment of bone diseases. , Can be used as a substitute for prevention and treatment of existing bone diseases in which side effects are present, and can also be used as a health food.
이하, 본 발명을 보다 상세히 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명은 당귀(Angelica gigas), 백작약(Paeoniae Radix Alba), 백출(Atractylodes macrocephala Koidzumi) 및 복령(Wolfiporia extensa) 추출물을 포함하고,The present invention relates to the use of Angelica gigas , Paeoniae Radix Alba, Atractylodes macrocephala Koidzumi and Wolfiporia extensa extract,
치자(Gardeniae Fructus), 감초(Glycyrrhiza uralensis, Licorice), 길경(도라지(Platycodon grandiflorum A. DC.)의 뿌리), 건강(Zingiberis Siccatum Rhizoma) 및 박하(Mentha arvensis var. piperascens)로 구성된 군으로부터 선택되는 어느 하나 이상의 추출물을 추가적으로 함유하는 골질환 예방 또는 치료용 약학적 조성물을 제공한다. Gardeniae Fructus ), licorice ( Glycyrrhiza uralensis , Licorice, Root of Platycodon grandiflorum A. DC), Health ( Zingiberis Siccatum Rhizoma) and mint ( Mentha arvensis there is. piperascens). The present invention also provides a pharmaceutical composition for preventing or treating bone diseases.
상기 조성물은 당귀, 백작약, 백출, 복령, 치자, 감초 및 길경 추출물을 포함하고,Wherein said composition comprises Angelica keiskei kei, Baekjak medicine, Baekjoo, Bokryeong, Gardenia, Licorice,
건강 또는 박하 추출물을 추가적으로 함유하는 것이 바람직하며, 더욱 바람직하게는 상기 조성물은 당귀, 백작약, 백출, 복령, 치자, 감초, 길경, 건강 및 박하 추출물을 함유하는 것이 바람직하나 이에 한정되지 않는다.Health, or peppermint extract, and more preferably, the composition includes, but is not limited to, Angelica keiskei, Veterinary medicine, Lycoris chejuensis, Bacillus cereus, Gardenia, Licorice, Ginkgo, Health and peppermint extract.
상기 조성물을 당귀 10 ~ 20 중량부, 백작약 10 ~ 20 중량부, 백출 10 ~ 20 중량부 및 복령 10 ~ 20 중량부로 구성된 추출물을 포함하고,Wherein said composition comprises 10 to 20 parts by weight of Angelica gigas Nakai, 10 to 20 parts by weight of Baekjong medicine, 10 to 20 parts by weight of Baekje, and 10 to 20 parts by weight of Baekjil,
치자 5 ~ 15 중량부, 감초 5 ~ 15 중량부, 길경 5 ~ 15 중량부, 건강 1 ~ 10 중량부 및 박하 1 ~ 10 중량부로 구성된 군으로부터 선택되는 어느 하나 이상의 추출물을 추가적으로 함유하는 것이 바람직하다.5 to 15 parts by weight of germanium, 5 to 15 parts by weight of licorice, 5 to 15 parts by weight of germanium, 1 to 10 parts by weight of health and 1 to 10 parts by weight of peppermint are further preferably contained .
또한, 당귀 15 중량부, 백작약 15 중량부, 백출 15 중량부, 복령 15 중량부 및 치자 10 중량부로 구성된 추출물을 포함하고,Also included were an extract consisting of 15 parts by weight of Angelica keiskei koidz., 15 parts by weight vetch, 15 parts by weight of alum, 15 parts by weight of germanium and 10 parts by weight of gardenia,
감초 10 중량부, 길경 10 중량부, 건강 5 중량부 및 박하 5 중량부로 구성된 군으로부터 선택되는 어느 하나 이상의 추출물을 추가적으로 함유하는 것이 바람직하나 이에 한정되지 않으며, 더욱 바람직하게는 당귀 15 중량부, 백작약 15 중량부, 백출 15 중량부, 복령 15 중량부, 치자 10 중량부, 감초 10 중량부, 길경 10 중량부, 건강 5 중량부 및 박하 5 중량부로 구성된 추출물을 함유하는 것이 바람직하다.10 parts by weight of licorice, 10 parts by weight of ginseng, 5 parts by weight of health, and 5 parts by weight of peppermint are further preferably added but not limited thereto. More preferably, 15 parts by weight of Angelica gigantosa, 15 parts by weight, 15 parts by weight, 15 parts by weight of gum, 10 parts by weight of gardenia, 10 parts by weight of licorice, 10 parts by weight of gum, 5 parts by weight of health and 5 parts by weight of peppermint.
상기 생약재 추출물은 하기의 단계들을 포함하는 제조방법에 의해 제조되는 것이 바람직하나 이에 한정하지 않는다.The herbal medicine extract is preferably, but not necessarily, prepared by a manufacturing method comprising the following steps.
1) 당귀, 백작약, 백출, 복령, 치자, 감초, 길경, 건강 및 박하 혼합물에 추출용매를 가하여 추출하는 단계;1) Extracting a mixture of Angelica gigas Nakai, Veterinary medicine, Baekyoung, Gyungyoung, Gardenia, Licorice, Gyeonggyeong, Health and Mint mixture with an extraction solvent;
2) 단계 1)의 추출물을 식힌 후 여과하는 단계; 및2) cooling the extract of step 1) and filtering; And
3) 단계 2)의 여과한 추출물을 감압 농축한 후 건조하는 단계.3) Concentrating the filtered extract of step 2) under reduced pressure and drying.
상기 방법에 있어서, 단계 1)의 추출용매는 물, C1 내지 C2 저급 알코올 또는 이들의 혼합물을 용매로 하여 추출하는 것이 바람직하며, 상기 저급 알코올은 에탄올 또는 메탄올인 것이 바람직하나, 이에 한정되는 것은 아니다. 상기 추출용매는 건조된 혼합 생약재에 0.1 내지 10배로 하고, 더욱 바람직하게는 0.3 내지 5배 첨가하는 것이 바람직하나 이에 한정되지 않는다. 추출온도는 20 내지 70℃인 것이 바람직하나, 이에 한정되지 않는다. 또한, 추출시간은 12 내지 48시간인 것일 수 있으나, 이에 한정되지 않는다. 상기 방법에 있어서, 단계 3)의 감압농축은 진공감압농축기 또는 진공회전증발기를 이용하는 것일 수 있으나 이에 한정되지 않는다. 또한, 건조는 감압건조, 진공건조, 비등건조, 분무건조 또는 동결건조 하는 것일 수 있으나 이에 한정하지 않는다. In this method, the extraction solvent of step 1) is preferably extracted with water, C 1 to C 2 lower alcohol or a mixture thereof, and the lower alcohol is preferably ethanol or methanol, It is not. The extraction solvent is preferably added in an amount of 0.1 to 10 times, more preferably 0.3 to 5 times, to the dried mixed herbal medicines, but is not limited thereto. The extraction temperature is preferably 20 to 70 DEG C, but is not limited thereto. In addition, the extraction time may be 12 to 48 hours, but is not limited thereto. In this method, the vacuum concentration of step 3) may be by using a vacuum decompression concentrator or a vacuum rotary evaporator, but is not limited thereto. The drying may be, but not limited to, vacuum drying, vacuum drying, boiling, spray drying or lyophilization.
상기 혼합추출물은 생약재를 혼합한 후 추출할 수 있고, 생약재 각각 추출한 추출물을 혼합하여 사용할 수 있으나, 이에 한정되지 않는다.The mixed extract may be extracted after mixing the herbal medicines, and the extracted extracts of the herbal medicines may be mixed and used, but the present invention is not limited thereto.
본 발명의 구체적인 실시예에서, 본 발명자들은 당귀, 백작약, 백출, 복령, 치자, 감초, 길경, 건강 및 박하 혼합 추출물의 골다공증 예방 및 치료 효과를 확인하기 위하여, 생약재 추출물을 제조하였다. 또한 본 발명자들은 골다공증을 유발시킨 정상 쥐(Sham군)와, 난소 절제 쥐군, 본 발명의 생약재 추출물을 용량별로 섭취시킨 쥐군에서 당귀, 백작약, 백출, 복령, 치자, 감초, 길경, 건강 및 박하 생약재 추출물의 골다공증 개선 효과를 확인하기 위하여 우선 일정기간 생약재 혼합물을 섞은 식이를 섭취시킨 후 동물의 체중 변화(표2 참조), 체중증가량, 식이섭취량 및 식이효율(표3 참조) 과 장기 무게(표4 참조)를 측정해 본 발명의 생약재 혼합물의 체내 안전성을 확인하였다. In a specific example of the present invention, the present inventors prepared a herbal medicine extract in order to confirm the effect of preventing and treating osteoporosis in a mixed extract of Angelica gigas Nakai, Veterinary Medicine, Baekyoung, Gyungyu, Gardenia, Licorice, In addition, the present inventors have found that in the case of ovariectomized rats, ovariectomized rats, ovariectomized rats, ovariectomized rats, ovariectomized rats, osteoporosis, acanthopanax, licorice, licorice, licorice, (See Table 2), body weight gain, dietary intake and dietary efficiency (see Table 3) and organ weights (see Table 4), after the diets were mixed with a mixture of herbal medicines for a certain period of time ) Was measured to confirm the safety of the herbal medicament mixture of the present invention.
또한, 본 발명자들은 대퇴골 무게 및 길이(표 5 참조)와 Bone mineral density(표 6 참조), 혈액의 생화학지수(표 7 참조) 및 혈액의 칼슘과 인 함량(표 8)을 측정하였으며 그 결과 생약재 혼합물의 골다공증 개선 효과를 확인하였다.The inventors also measured the femur weight and length (see Table 5), bone mineral density (see Table 6), blood biochemical index (see Table 7) and blood calcium and phosphorus content (Table 8) The osteoporosis improvement effect of the mixture was confirmed.
또한, 본 발명자들은 본 발명의 생약재 혼합물을 섭취시 혈중 콜레스테롤 지수가 정상군에 비해 증가함을 확인하였다. 하지만 이는 양성 대조군에 비하면 양호한 수준임을 확인하였다.In addition, the present inventors have found that the blood cholesterol index is increased in comparison with the normal group when the herbal medicine mixture of the present invention is ingested. However, it was confirmed that this was better than the positive control group.
결론적으로, 본 발명인 당귀, 백작약, 백출, 복령, 치자, 감초, 길경, 건강 및 박하 혼합 추출물을 유효성분으로 포함하는 약학적 조성물 및 건강식품은 체내에서 안전한 효과를 보이며 대퇴골의 무게 및 길이 성장과 Bone mineral density 및 혈액 내 칼슘과 인 함량을 효과적으로 증가시키는 바, 골질환 예방 및 치료용으로 유용하게 사용될 수 있다.In conclusion, the pharmaceutical composition and the health food containing the mixed extract of Angelica gigantosa, Bacillus thuringiensis, Bacillus thuringiensis, Glycyrrhizae, Gardenia, Licorice, Bone mineral density and calcium and phosphorus content in the blood, and thus can be effectively used for prevention and treatment of bone diseases.
본 발명에 따른 조성물은 약제학적으로 유효한 양으로 투여한다. 본 발명에 있어서, "약제학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜 또는 위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효 용량 수준은 환자의 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료 기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명의 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고 종래의 치료제와는 순차적 또는 동시에 투여될 수 있으며, 단일 또는 다중 투여될 수 있다. 상기 요소들을 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 이는 당업자에 의해 용이하게 결정될 수 있다.The composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, the term " pharmaceutically effective amount " means an amount sufficient to treat a disease at a reasonable benefit or risk ratio applicable to medical treatment, and the effective dose level will depend on the type of disease, severity, , Sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including co-administered drugs, and other factors well known in the medical arts. The composition of the present invention can be administered as an individual therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents, and can be administered singly or in multiple doses. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without side effects, which can be easily determined by those skilled in the art.
구체적으로, 본 발명에 따른 조성물의 유효량은 환자의 나이, 성별, 체중에 따라 달라질 수 있으며, 일반적으로는 체중 1 kg 당 0.1 mg 내지 100 mg, 바람직하게는 0.2 mg 내지 17 mg을 매일 또는 격일로 투여하거나 1일 1회 내지 3회로 나누어 투여할 수 있다. 그러나 투여 경로, 비만의 중증도, 성별, 체중, 연령 등에 따라서 증감될 수 있으므로 상기 투여량이 어떠한 방법으로도 본 발명의 범위를 한정하는 것은 아니다.Specifically, the effective amount of the composition according to the present invention may vary depending on the age, sex, and body weight of the patient, and is generally in the range of 0.1 mg to 100 mg, preferably 0.2 mg to 17 mg per kg of body weight per day or every other day Or one to three times a day. However, the dosage may be varied depending on the route of administration, the severity of obesity, sex, weight, age, etc. Therefore, the dosage is not limited to the scope of the present invention by any means.
상기 혼합 생약재 추출물은 임상 투여 시에 경구 또는 비경구로 투여가 가능하며 일반적인 의약품 제제의 형태로 사용될 수 있다. 즉, 본 발명의 혼합 생약재 추출물은 실제 임상 투여 시에 경구 및 비경구의 여러 가지 제형으로 투여될 수 있는데, 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제 및 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구 투여를 위한 고형 제제에는 정제, 환제, 산제, 과립제 및 캡슐제 등이 포함되며, 이러한 고형 제제는 혼합 생약재 추출물에 적어도 하나 이상의 부형제 예를 들면, 전분, 탄산칼슘, 수크로스, 락토오스 및 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용된다. 경구 투여를 위한 액상 제제로는 현탁제, 내용액제, 유제 및 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제 및 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제 및 좌제가 포함된다. 비수성용제와 현탁용제로는 프로필렌글리콜, 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세롤 및 젤라틴 등이 사용될 수 있다. 투약 단위는, 예를 들면 개별 투약량의 1, 2, 3 또는 4배를 함유하거나 또는 1/2, 1/3 또는 1/4배를 함유할 수 있다. 개별투약량은 바람직하게는 유효 약물이 1회에 투여되는 양을 함유하며, 이는 통상 1일 투여량의 전부, 1/2, 1/3 또는 1/4배에 해당한다. 혼합 생약재 추출물의 유효용량은 10 내지 1,000 ㎎/㎏이고, 바람직하게는 30 내지 3,000 mg/kg이며, 하루 1-6 회 투여될 수 있다.The mixed herbal extract may be administered orally or parenterally at the time of clinical administration and may be used in the form of a general pharmaceutical preparation. That is, the mixed herbal medicine extract of the present invention may be administered in various formulations of oral or parenteral administration at the time of actual clinical administration. In the case of formulation, diluents such as fillers, extenders, binders, humectants, disintegrants, Or an excipient. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, lactose and gelatin . In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Liquid preparations for oral administration include suspensions, solutions, emulsions and syrups. Various excipients such as wetting agents, sweeteners, fragrances and preservatives may be included in addition to water and liquid paraffin, which are commonly used simple diluents. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations and suppositories. Examples of the non-aqueous solvent and the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. As the base of the suppository, witepsol, macrogol, tween 61, cacao paper, laurin, glycerol and gelatin can be used. The dosage unit may contain, for example, 1, 2, 3 or 4 times the individual dose or may contain 1/2, 1/3 or 1/4 times the dose. The individual dosages preferably contain amounts in which the active drug is administered in a single dose, which usually corresponds to the full, half, one-third or one-fourth of the daily dose. The effective dose of the mixed herbal extract is 10 to 1,000 mg / kg, preferably 30 to 3,000 mg / kg, and can be administered 1-6 times a day.
또한, 본 발명은 당귀, 백작약, 백출 및 복령 추출물을 포함하고,The present invention also relates to a composition containing Angelica keiskei koidz., Veterinary medicine,
치자, 감초, 길경, 건강 및 박하로 구성된 군으로부터 선택되는 어느 하나 이상의 추출물을 추가적으로 함유하는 골질환 예방 또는 개선용 건강식품을 제공한다.There is provided a health food for preventing or ameliorating bone diseases, which additionally contains any one or more extracts selected from the group consisting of gardenia, licorice, Jilin, health, and peppermint.
상기 건강식품은 당귀, 백작약, 백출, 복령, 치자, 감초 및 길경 추출물을 포함하고,The health food includes Angelica keiskei, Veterinary medicine, Bacillus sp., Bacillus sp., Gardenia sp., Licorice root,
건강 또는 박하 추출물을 추가적으로 함유하는 것이 바람직하며, 더욱 바람직하게는 당귀, 백작약, 백출, 복령, 치자, 감초, 길경, 건강 및 박하 추출물을 함유하는 것이 바람직하나 이에 한정되지 않는다.Health, or peppermint extract, and more preferably, it contains, but not limited to, Angelica keiskei, Veterinary medicine, Lycoris chejuensis, Bacillus cereus, Gardenia, Licorice root,
상기 건강식품은 당귀 10 ~ 20 중량부, 백작약 10 ~ 20 중량부, 백출 10 ~ 20 중량부 및 복령 10 ~ 20 중량부로 구성된 추출물을 포함하고,Wherein the health food comprises an extract consisting of 10-20 parts by weight of Angelica gigas, 10-20 parts by weight of a vinegar, 10-20 parts by weight of an extract and 10-20 parts by weight of a sea tangle,
치자 5 ~ 15 중량부, 감초 5 ~ 15 중량부, 길경 5 ~ 15 중량부, 건강 1 ~ 10 중량부 및 박하 1 ~ 10 중량부로 구성된 군으로부터 선택되는 어느 하나 이상의 추출물을 추가적으로 함유하는 것이 바람직하다.5 to 15 parts by weight of germanium, 5 to 15 parts by weight of licorice, 5 to 15 parts by weight of germanium, 1 to 10 parts by weight of health and 1 to 10 parts by weight of peppermint are further preferably contained .
또한, 당귀 15 중량부, 백작약 15 중량부, 백출 15 중량부, 복령 15 중량부 및 치자 10 중량부로 구성된 추출물을 포함하고,Also included were an extract consisting of 15 parts by weight of Angelica keiskei koidz., 15 parts by weight vetch, 15 parts by weight of alum, 15 parts by weight of germanium and 10 parts by weight of gardenia,
감초 10 중량부, 길경 10 중량부, 건강 5 중량부 및 박하 5 중량부로 구성된 군으로부터 선택되는 어느 하나 이상의 추출물을 추가적으로 함유하는 것이 바람직하나 이에 한정되지 않으며, 더욱 바람직하게는 당귀 15 중량부, 백작약 15 중량부, 백출 15 중량부, 복령 15 중량부, 치자 10 중량부, 감초 10 중량부, 길경 10 중량부, 건강 5 중량부 및 박하 5 중량부로 구성된 추출물을 함유하는 것이 바람직하다.10 parts by weight of licorice, 10 parts by weight of ginseng, 5 parts by weight of health, and 5 parts by weight of peppermint are further preferably added but not limited thereto. More preferably, 15 parts by weight of Angelica gigantosa, 15 parts by weight, 15 parts by weight, 15 parts by weight of gum, 10 parts by weight of gardenia, 10 parts by weight of licorice, 10 parts by weight of gum, 5 parts by weight of health and 5 parts by weight of peppermint.
본 발명의 당귀, 백작약, 백출, 복령, 치자, 감초, 길경, 건강 및 박하 혼합 추출물은 골다공증을 유발시킨 난소 절제한 쥐군에서 유의적인 대퇴골 무게와 길이 증가와 Bone mineral density의 증가를 보였으며 체내 안전성이 입증되었고 양성 대조군과 비교해 본 결과 우수한 골다공증 예방 또는 개선 효과를 나타냄을 확인하였다. 따라서 상기 당귀, 백작약, 백출, 복령, 치자, 감초, 길경, 건강 및 박하 혼합 추출물은 골다공증 예방 또는 개선을 위한 건강식품으로 유용하게 사용될 수 있음을 확인하였다.The combined extracts of Angelica gigas Nakai, Baekjaek, Baekyoung, Gyungyong, Gardenia, Licorice, Gyungyang, Healthy, and Mint of the present invention showed significant increase in femur weight and length and bone mineral density in ovariectomized rats that caused osteoporosis. And it was confirmed that it showed excellent osteoporosis prevention or improvement effect as compared with the positive control group. Therefore, it was confirmed that the mixed extracts of Angelica gigas, Glycyrrhiza uralensis, Bacillus sp., Bacillus sp., Gardenia, Licorice, Gakgyeong, Health and Mint can be effectively used as a health food for preventing or improving osteoporosis.
상기 식품의 종류에는 특별한 제한은 없다. 상기 물질을 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 쵸코렛, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다. 본 발명의 상황버섯 및 단삼 혼합추출물을 식품 첨가물로 사용할 경우, 상기 추출물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효 성분의 혼합양은 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 건강식품 중의 상기 화합물의 양은 전체 식품 중량의 0.1 내지 90 중량부로 가할 수 있다. 그러나 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다.There is no particular limitation on the kind of the food. Examples of the food to which the above substances can be added include dairy products including meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, Alcoholic beverages, and vitamin complexes, all of which include healthy foods in a conventional sense. When the mixture of the mushroom and radish mixed extract of the present invention is used as a food additive, the extract can be used as it is, or can be used together with other food or food ingredients, and can be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (prevention, health or therapeutic treatment). Generally, the amount of the compound in the health food may be 0.1 to 90 parts by weight of the total food. However, in the case of long-term intake intended for health and hygiene purposes or for the purpose of controlling health, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range.
본 발명의 건강 음료 조성물은 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 슈크로스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 향미제나, 사카린, 아스파르탐과 같은 합성 향미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 g 당 일반적으로 약 1 내지 20 g, 바람직하게는 약 5 내지 12 g 이다. 상기 외에 본 발명의 상황버섯 및 단삼 혼합추출물은 여러가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 상황버섯 및 단삼 혼합추출물은 천연 과일쥬스, 과일쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다.The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. As the sweetening agent, natural flavors such as tau Martin and stevia extract, synthetic flavors such as saccharin and aspartame, and the like can be used. The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 g of the composition of the present invention. In addition to the above, the mushroom and ragwort mixed extract of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, Glycerin, alcohols, carbonating agents used in carbonated beverages, and the like. In addition, the mushroom and radish mixed extract of the present invention may contain flesh for the production of natural fruit juice, fruit juice drink and vegetable drink. These components may be used independently or in combination.
이하, 본 발명을 실시예, 실험예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail with reference to Examples and Experimental Examples.
단, 하기 실시예, 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예 및 실험예에 의해 한정되는 것은 아니다.However, the following examples and experimental examples are illustrative of the present invention, and the content of the present invention is not limited by the following examples and experimental examples.
<< 실시예Example 1> 혼합 1> Mix 생약재Herbal medicine 추출물의 제조 Preparation of extract
<1-1> <1-1> 생약재Herbal medicine 선별 및 전처리 공정 Screening and Pretreatment Process
당귀 150 g, 백작약 150 g, 백출 150 g, 복령 150 g, 치자 100 g, 감초 100 g, 길경 100 g, 건강 50 g 및 박하 50 g 을 이물질을 제거한 다음 추출이 용이하도록 5 cm 내외로 세절하고 물로 깨끗이 세척하였다. 생약재들을 세절한 것은 그 취급과 추출을 용이하게 하기 위함이다.150 g of Angelica gigantosa, 150 g of whitening agent, 150 g of gum, 150 g of gum, 150 g of gardenia, 100 g of licorice, 100 g of licorice, 100 g of gum, 50 g of health and 50 g of peppermint. Washed thoroughly with water. The trimming of herbal medicines is to facilitate their handling and extraction.
<1-2> <1-2> 생약재Herbal medicine 열수Heat number 추출물의 제조 Preparation of extract
상기 공정에서 얻어진 재료를 추출장치에 넣고 추출용매로 추출하였다. 추출용매로 순수한 물을 생약재 대비 5배를 첨가하여 냉각추출 장치로 95℃에서 6시간 추출하였다. 추출액을 1-2시간 자연 첨지한 후 면헝겊 여과지로 여과하여 생약재와 열수 추출액을 분리하였다. 여과된 열수추출액을 감압 농축하여 동결건조로 수분을 제거함으로써 생약재 열수 추출물을 수득하였다. The material obtained in the above process was put into an extraction device and extracted with an extraction solvent. Pure water as an extraction solvent was added 5 times as much as the herbal medicines and extracted with a cooling extraction apparatus at 95 ° C for 6 hours. The extracts were spontaneously spiked for 1-2 hours and then filtered with a cloth filter paper to separate the herbal medicines and the hot water extract. The filtered hot water extract solution was concentrated under reduced pressure and the water was removed by freeze drying to obtain a hot water extract of a herbal medicine.
<1-3> <1-3> 생약재Herbal medicine 에탄올 추출물의 제조 Preparation of ethanol extract
상기 공정에서 얻어진 재료에 95% 에탄올을 생약재 대비 5배를 첨가한 다음 80℃에서 교반 반응기에서 12시간 이상 추출한 후 필터를 이용하여 거르고 원심분리(5,000 rpm, 4℃, 10분)하여 얻은 상징액을 동결건조하여 생약재 에탄올 추출물을 수득하였다.To the material obtained in the above process, 95% ethanol was added 5 times as much as the herbal medicines, and the mixture was extracted with a stirring reactor at 80 ° C for at least 12 hours, filtered using a filter, centrifuged (5,000 rpm, 4 ° C, 10 minutes) And lyophilized to obtain a herbal medicine ethanol extract.
<< 실험예Experimental Example 1> 골다공증 모델의 난소 적출 흰쥐에 대한 동물 실험 1> Animal experiments on ovariectomized rats in osteoporosis model
<1-1> 실험동물 준비 및 사육<1-1> Preparation and breeding of experimental animals
특정병원체(specific pathogen free)가 없는 6주령의 난소를 적출한 암컷 ICR mouse((주)두열바이오텍)를 구입하여 사용하였다. 구입한 쥐는 1주일간의 검역과 적응 과정을 거친 뒤 체중 감소가 없는 건강한 쥐를 선별해 실험용으로 사용하였다. 실험쥐는 온도 23 ± 3℃, 상대습도 50 ± 10 %, 환기회수 10-15회/시간, 조명시간 12시간(08:00 ~ 20:00), 조도 150 ~ 300 Lux로 설정된 사육환경에서 사육되었으며, 1주간의 적응기간 동안 실험동물용 고형사료 ((주)카길애그리퓨리나, 군산, 한국)와 음수를 자유롭게 섭취하였다.A female ICR mouse (Dooyol Biotech Co., Ltd.) was used, from which 6-week-old ovaries were isolated without specific pathogen-free pathogen. Purchased rats were selected for healthy rats without a weight loss after 1 week of quarantine and adaptation and used for the experiment. Experimental rats were housed in a raising environment with a temperature of 23 ± 3 ℃, a relative humidity of 50 ± 10%, a ventilation frequency of 10-15 times / hour, a lighting time of 12 hours (08:00 ~ 20:00) . During the adaptation period of 1 week, the animals were freely consecutively fed with a solid feed for experimental animals (Cargill Agri Purina, Gunsan, Korea).
<1-2> 골다공증 유발 및 약물투여<1-2> Osteoporosis induction and drug administration
1주간의 적응기간을 거친 후 건강한 동물을 선별하여 난괴법에 의거하여 6개의 군으로 분류하였다. 즉 실험군은 정상대조군인 샴(sham)군, 난소절제 마우스군, 난소절제 마우스에 실시예 <1-1>에서 제조한 생약재 추출물을 300 mg/kg/day의 농도로 식이섭취한 군, 난소절제 마우스에 생약재 추출물을 600 mg/kg/day의 농도로 식이섭취한 군, 난소절제 마우스에 생약재 추출물을 900 mg/kg/day의 농도로 식이섭취한 군, 양성 대조물질(종근당, 건강튼튼관절)을 400 mg/kg/day 농도로 식이섭취한 양성대조군으로 분류하여 실험을 진행하였다. After 1 week of adaptation period, healthy animals were selected and classified into 6 groups based on the nodule method. That is, the experimental group was fed with the herbal medicine extract prepared in Example <1-1> at a dose of 300 mg / kg / day to the sham group, the ovariectomized mouse group, and the ovariectomized mouse in the normal control group, The mice were fed a diet containing 600 mg / kg / day of herbal extracts, 900 mg / kg / day of herbal extracts in ovariectomized rats, positive control (Chong Kun Dang, healthy dart joints) Were grouped into positive control group (400 mg / kg / day).
모든 실험군에 기본식이 AIN-93 diet(Research Diets, Inc. (New Brunswick. NJ, USA) (표 1 참조)를 6주간 섭취시켰으며, 골다공증을 발병시킨 후, 생약재 추출물이 함유된 식이를 각각 정량별로 8주간 공급하였다. 실험기간동안 식이와 음수는 자유로이 섭취하도록 하였다.All diets were fed a basic diet of AIN-93 diet (Research Diets, Inc., New Brunswick, NJ, USA) (see Table 1) for 6 weeks. After the onset of osteoporosis, diets containing herbal extracts were quantified Were fed for 8 weeks. During the experimental period, diets and negative water were freely consumed.
<1-3> 약물 투여에 의한 체중 변화 및, 체중증가량, ≪ 1-3 > Weight change, weight gain, 식이섭취량Dietary intake 및 And 식이효율 측정Eating efficiency measurement ..
상기 <1-2>의 방법에 의해 혼합 생약재 추출물이 투여된 실험동물의 체중을 매주 측정하고, 일정기간 투여 후 체중증가량, 식이섭취량 및 식이효율을 측정하여 샴군과 실험군 및 대조군의 체중을 비교하였다. 동물의 체중변화는 표 2에 나타내었으며, 동물의 체중증가량, 식이섭취량 및 식이효율은 표 3에 나타내었다.The body weights of the experimental animals administered with the mixed herbal medicine extracts were measured weekly by the method of <1-2>, and the weight gain, the dietary intake and the diet efficiency were measured after administration for a certain period of time to compare the body weights of the Shamshuman group, the experimental group and the control group . The body weight changes of the animals are shown in Table 2, and the weight gain, the dietary intake, and the diet efficiency of the animals are shown in Table 3.
표 2에 나타난 바와 같이, 난소절제 마우스 군의 경우 샴군과 비교하여 급격한 체중 증가를 나타내었으며, 본 발명 생약재 추출물의 900 mg/kg/day의 투여군은 양성 대조군과 유사한 체중 증가를 나타내었다.As shown in Table 2, the ovariectomized mouse group showed a rapid increase in body weight as compared with the Sham group, and the 900 mg / kg / day group of the herbal extract of the present invention showed a weight gain similar to that of the positive control group.
또한, 표 3에 나타난 바와 같이 본 발명의 생약재 추출물의 섭취량이 증가함에 따라 식이효율은 증가하지 않았으며, 샴군과 난소절제 마우스 군의 중간 정도의 식이효율을 나타냄을 확인하였다.As shown in Table 3, the dietary efficiency was not increased as the intake of the herbal medicine extract of the present invention was increased, and it was confirmed that the dietary efficiency was moderate between the sham group and the ovariectomized mouse group.
따라서 본 발명의 생약재 추출물은 난소절제 마우스 군과 양성대조군을 비교하여 체중 변화 및 식이섭취량, 식이 효율에 영향을 주지 않고 체내 호르몬의 변화가 없어 안전함을 확인하였다. Therefore, the herbal medicine extract of the present invention was compared with the ovariectomized mouse group and the positive control group, and it was confirmed that there was no change in body hormone and it was safe without affecting body weight change, dietary intake and diet efficiency.
(mg/kg/day)Herbal medicine extract
(mg / kg / day)
대조군
(mg/kg/day)positivity
Control group
(mg / kg / day)
Values are expressed as mean ± SEMValues are expressed as mean ± SEM
* p < 0.05, ** p < 0.01, *** p < 0.001 compared with the A group. * p <0.05, ** p <0.01, *** p <0.001 compared with the group.
# p < 0.05, ## p < 0.01, ### p < 0.001 compared with the B group. # p < 0.05, ## p < 0.01, ### p < 0.001 compared with the B group.
(mg/kg/day)Mixed herbal extract
(mg / kg / day)
대조군
(mg/kg/day)positivity
Control group
(mg / kg / day)
(g/day)Body weight gain
(g / day)
(g/day)Food intake
(g / day)
Values are expressed as mean ± SEMValues are expressed as mean ± SEM
* p < 0.05, ** p < 0.01, *** p < 0.001 compared with the A group. * p <0.05, ** p <0.01, *** p <0.001 compared with the group.
# p < 0.05, ## p < 0.01, ### p < 0.001 compared with the B group. # p < 0.05, ## p < 0.01, ### p < 0.001 compared with the B group.
<1-4> 약물 투여에 의한 장기무게 변화 측정<1-4> Measurement of organ weight change by drug administration
상기 <1-2>의 방법에 의해 생약재 추출물을 일정기간 투여 후 실험동물의 장기무게를 측정하여 샴군, 실험군 및 대조군의 장기무게를 비교하였다. 동물의 장기무게 변화는 표 4에 나타내었다.The organ weight of the experimental animals was measured by the method of <1-2> after the herbal medicine extract was administered for a predetermined period, and the organ weights of the sham group, the experimental group and the control group were compared. The organ weight changes of the animals are shown in Table 4.
표 4에 나타난 바와 같이 난소절제 마우스 군의 경우 샴군에 비해 장기의 무게가 전반적으로 증가하였다. 반면 실험군의 경우 생약재 추출물의 섭취량이 증가함에 따라 장기 무게가 감소하였으며 정상군 수준으로 회복됨을 확인하였고, 생약재 추출물을 900 mg/kg/day 투여군은 양성대조군과 유사한 장기 무게를 나타냄을 확인하였다.As shown in Table 4, in the ovariectomized mouse group, the organs weighed overall compared to the sham group. On the other hand, in the experimental group, it was confirmed that the weight of organs decreased as the intake of the herbal medicine extract increased and recovered to the normal group level, and 900 mg / kg / day of the herbal medicine extract group showed similar organs weight as the positive control group.
따라서 본 발명의 생약재 추출물은 샴군 및 양성 대조군과 비교하여 전반적으로 장기 무게에 변화를 주지 않아 체내 섭취되었을 때 안전한 것을 확인하였다.Therefore, the herbal medicine extract of the present invention was found to be safe when ingested in the body, since it did not change the long-term weight as a whole compared with the sham group and the positive control group.
(mg/kg/day)Mixed herbal extract
(mg / kg / day)
대조군
(mg/kg/day)positivity
Control group
(mg / kg / day)
(g)Liver
(g)
(g)Spleen
(g)
(g)Kidney (left)
(g)
(g)Kidney (right)
(g)
Values are expressed as mean ± SEMValues are expressed as mean ± SEM
* p < 0.05, ** p < 0.01, *** p < 0.001 compared with the A group. * p <0.05, ** p <0.01, *** p <0.001 compared with the group.
# p < 0.05, ## p < 0.01, ### p < 0.001 compared with the B group. # p < 0.05, ## p < 0.01, ### p < 0.001 compared with the B group.
<1-5> 대퇴골 무게 및 길이 변화와 골밀도 측정<1-5> Changes in femur weight and length and bone mineral density
부검 당일 채혈 후 실험동물의 대퇴골을 적출하여 골격에 붙어 있는 근육, 인대 및 지방을 제거한 후 대퇴골의 무게 및 길이를 측정한 후, 골밀도측정기(PIXImusTM, GELUVAR, Medison, WI, USA)를 사용하여 골밀도 (Bone mineral density, BMD)를 측정하였다. 대퇴골의 무게 및 길이는 표 5에 나타내었으며 골밀도는 표 6에 나타내었다.On the day of the autopsy, the femur was removed from the test animals and the muscle, ligament, and fat attached to the skeleton were removed, and the weight and length of the femur were measured. The bone mass was measured using a bone mineral density meter (PIXImus TM , GELUVAR, Medison, WI, USA) was used to measure bone mineral density (BMD). The weight and length of the femur are shown in Table 5 and the bone density is shown in Table 6.
그 결과, 표 5에 나타낸 바와 같이 샴군과 비교하였을 때 난소 절제 마우스군에서 대퇴골의 무게와 길이가 급격히 증가하였으며, 생약재 혼합 추출물 투여군에서도 대퇴골의 무게 및 길이가 증가하였고 투여량을 증가시킴에 따라 뼈의 무게와 길이가 비례해 증가하였다. 생약재 혼합 추출물 900 mg/kg/day 투여군의 경우 양성 대조군과 샴군의 골질량 및 골길이의 1/2 정도의 수치를 나타냈다.As a result, as shown in Table 5, the weight and length of the femur increased rapidly in the ovariectomized mouse group as compared with that of the sham group, and the weight and length of the femur increased in the group treated with the herbal medicine mixed extract. And the weight and length of each of them increased in proportion. In the 900 mg / kg / day group of mixed extracts of herbal medicines, the values of bone mass and bone length of the positive control group and sham group were about 1/2.
반면, Bone mineral density(BMD)의 경우 표 6에 나타낸 바와 같이 난소 절제 마우스 군에서 BMD값이 급격히 감소되었으며, 생약재 혼합 추출물 투여군에서는 투여량이 증가함에 따라 골밀도가 증가 양상을 보였고, 생약재 혼합 추출물 900 mg/kg/day 투여군의 경우 양성 대조군과 차이가 없는 것을 확인하였다.As shown in Table 6, bone mineral density (BMD) decreased rapidly in the ovariectomized mouse group. In the group treated with the herbal medicine mixed extract, the bone mineral density increased with the increase in the dose, and 900 mg / kg / day group did not differ from the positive control group.
따라서 난소 절제 마우스 군의 경우 대퇴골 무게 및 길이가 증가하는 정도에 비해 BMD가 감소된바 골다공증이 유발되었다는 것을 확인하였으며 본 발명의 생약재 추출물 투여군은 대퇴골의 무게 및 길이 증가와 함께 BMD도 증가하였으며, 양성대조군과 큰 차이를 나타내지 않았는바, 골다공증 예방 및 치료에 유의적인 효과가 있음을 확인하였다.Therefore, it was confirmed that the ovariectomized mouse group resulted in osteoporosis due to a decrease in BMD compared to the increase in the weight and length of the femur. In the group administered with the herbal medicine extract of the present invention, BMD was increased with increasing the weight and length of the femur, And there was no significant difference from the control group, and it was confirmed that there was a significant effect on prevention and treatment of osteoporosis.
(mg/kg/day)Herbal medicine extract
(mg / kg / day)
대조군
(mg/kg/day)positivity
Control group
(mg / kg / day)
(mg)Bone weight
(mg)
(mm)Bone length
(mm)
Values are expressed as mean ± SEMValues are expressed as mean ± SEM
* p < 0.05, ** p < 0.01, *** p < 0.001 compared with the A group. * p <0.05, ** p <0.01, *** p <0.001 compared with the group.
# p < 0.05, ## p < 0.01, ### p < 0.001 compared with the B ## p < 0.01, ### p < 0.001 compared with the B group. # P <0.05, ## p < 0.01, ### p <0.001 compared with the B ## p <0.01, ### p <0.001 compared with the B group.
(mg/kg/day)Herbal medicine extract
(mg / kg / day)
대조군
(mg/kg/day)positivity
Control group
(mg / kg / day)
(g/cm2)BMD
(g / cm 2 )
Values are expressed as mean ± SEMValues are expressed as mean ± SEM
* p < 0.05, ** p < 0.01, *** p < 0.001 compared with the A group. * p <0.05, ** p <0.01, *** p <0.001 compared with the group.
# p < 0.05, ## p < 0.01, ### p < 0.001 compared with the B group. # p < 0.05, ## p < 0.01, ### p < 0.001 compared with the B group.
<1-6> 혈액의 생화학지수 측정<1-6> Measurement of blood biochemical index
실험동물을 희생 전 12시간 동안 절식시킨 후 트리브로모에탄올(tribromoethanol)을 3-아밀알코올(tertiary amylalcohol)로 희석하여 만든 마취제를 사용하여 마취한 후 안와채혈을 하였다. 혈액은 혈장 분리 튜브 (plasma separate tube)(Becton Dickinson, USA)에 담아 30분간 실온에서 방치하고 3,000 rpm에서 20분간 원심 분리하여 혈장을 분리하였고, 분석 전까지 -70℃에 보관하였다.The animals were fasted for 12 hours before sacrifice, and anesthesia was made using anesthetic prepared by diluting tribromoethanol with tertiary amyl alcohol, and orbital blood was collected. Blood was placed in a plasma separate tube (Becton Dickinson, USA), left at room temperature for 30 minutes, centrifuged at 3,000 rpm for 20 minutes, and the plasma was separated and stored at -70 ° C until analysis.
부검 당일 채취된 혈액에서 분리한 혈청을 혈액생화학분석기 (KoneLab 20 XT, Thermo Fisher Scientific, Waltham, Finland)를 이용하여 아스파르트산아미노기전달효소(aspartate aminotransferase ; AST), 알라닌아미노기전달효소(alanine aminotransferase ; ALT), 중성지방(Triglycerides, TG), 총콜레스테롤(Total cholesterol, TC), 고밀도지단백질(high density lipoprotein; HDL)-콜레스테롤 및 저밀도지단백질(low density lipoprotein; LDL)-콜레스테롤을 측정하였다.Serum isolated from the blood samples collected on the day of the autopsy was analyzed by aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alanine aminotransferase (ALT) using a blood biochemical analyzer (KoneLab 20 XT, Thermo Fisher Scientific, Waltham, Finland) ), Triglycerides (TG), total cholesterol (TC), high density lipoprotein (HDL) - cholesterol and low density lipoprotein (LDL) - cholesterol were measured.
그 결과, 표 7에 나타난 바와 같이, 샴군에 비해 난소 절제 마우스군에서 총 콜레스테롤 수치(TC)가 증가 하였다. 본 발명의 생약재 추출물 섭취군의 경우 생약재 추출물 섭취양이 증가함에 따라 전반적으로 총 콜레스테롤양이 증가하였다. 하지만 양성 대조군에 비해서는 그 증가 정도가 크지 않았다.As a result, as shown in Table 7, the total cholesterol level (TC) was increased in the ovariectomized mouse group compared to the Sham group. In the case of the herbal medicine extract group of the present invention, the total cholesterol level was increased as the intake of the herbal medicine extract increased. However, the increase was not significant compared with the positive control group.
따라서 생약재 추출물을 섭취시 전반적인 체내 콜레스테롤 양이 증가할 수 있으나 이는 양성 대조군을 섭취하였을 경우와 비교해 보았을 때 그 증가량이 크지 않고 양성 대조군에 비해 체내에 주는 영향이 적어 비교적 안전함을 확인하였다.Therefore, the total amount of cholesterol in the body can be increased when the herbal medicine extract is taken, but it is relatively safe compared to the case of taking the positive control group.
(mg/kg/day)Herbal medicine extract
(mg / kg / day)
대조군
(mg/kg/day)positivity
Control group
(mg / kg / day)
(mg/dl)TC
(mg / dl)
(mg/dl)HDL
(mg / dl)
(mg/dl)LDL
(mg / dl)
(mg/dl)TG
(mg / dl)
Values are expressed as mean ± SEMValues are expressed as mean ± SEM
* p < 0.05, ** p < 0.01, *** p < 0.001 compared with the A group. * p <0.05, ** p <0.01, *** p <0.001 compared with the group.
# p < 0.05, ## p < 0.01, ### p < 0.001 compared with the B group. # p < 0.05, ## p < 0.01, ### p < 0.001 compared with the B group.
<1-7> 혈액의 칼슘과 인 함량 측정<1-7> Measurement of blood calcium and phosphorus content
상기 <1-6의> 방법에 따라 채취한 혈액의 칼슘과 인 함량을 측정하였으며 그 결과를 표 8에 나타내었다.Calcium and phosphorus contents of blood collected according to the method of <1-6> were measured, and the results are shown in Table 8.
그 결과, 표 8에 나타난 바와 같이, 난소 절제 마우스군의 경우 칼슘과 인 함량이 샴군에 비해 감소하였으며 본 발명의 생약재 추출물 300 mg/kg/day 투여군의 경우 샴군 수준의 칼슘과 인 함량을 나타내었고 본 발명의 생약재 추출물 투여량이 증가함에 비례하여 혈액 내 칼슘과 인 함유량이 유의적으로 증가하였다.As a result, as shown in Table 8, the ovariectomized mouse group showed a decrease in calcium and phosphorus content compared with the sham group, and the calcium and phosphorus levels of the sham group were 300 mg / kg / day of the herbal medicine extract of the present invention The calcium and phosphorus contents in the blood were significantly increased in proportion to the dose of the herbal medicine extract of the present invention.
따라서 본 발명의 생약재 추출물은 난소 절제군 및 샴군과 비교하여 혈액 내 뼈를 구성하는 주요 원소인 칼슘과 인 함량 증가시키는 바, 골다공증 예방 및 치료에 효과적으로 사용될 수 있음을 확인하였다.Therefore, it is confirmed that the herbal medicine extract of the present invention increases calcium and phosphorus contents, which are the main constituents of bone in the blood, as compared with ovariectomized group and sham group, and thus it can be effectively used for prevention and treatment of osteoporosis.
(mg/kg/day)Herbal medicine extract
(mg / kg / day)
대조군
(mg/kg/day)positivity
Control group
(mg / kg / day)
(mg/dl)Ca
(mg / dl)
(mg/dl)P
(mg / dl)
Values are expressed as mean ± SEMValues are expressed as mean ± SEM
* p < 0.05, ** p < 0.01, *** p < 0.001 compared with the A group. * p <0.05, ** p <0.01, *** p <0.001 compared with the group.
# p < 0.05, ## p < 0.01, ### p < 0.001 compared with the B group. # p < 0.05, ## p < 0.01, ### p < 0.001 compared with the B group.
Claims (13)
It is known that Angelica gigas , Paeoniae radix Alba, Atractylodes macrocephala Koidzumi, Wolfiporia extensa , Gardeniae fructus , Glycyrrhiza uralensis , Licorice, Platycodon grandiflorum A. DC. ), Health ( Zingiberis Siccatum Rhizoma), and peppermint ( Mentha arvensis var. Piperascens) as an active ingredient.
당귀 추출물 10 ~ 20 중량부, 백작약 추출물 10 ~ 20 중량부, 백출 추출물 10 ~ 20 중량부, 복령 추출물 10 ~ 20 중량부, 치자 추출물 5 ~ 15 중량부, 감초 추출물 5 ~ 15 중량부, 길경 추출물 5 ~ 15 중량부, 건강 추출물 1 ~ 10 중량부 및 박하 추출물 1 ~ 10 중량부인 것을 특징으로 하는 골질환 예방 또는 치료용 약학적 조성물.
2. The composition of claim 1,
10-20 parts by weight of Angelica gigantosa extract, 10-20 parts by weight of Baekjang extract, 10-20 parts by weight of extract, 10-20 parts by weight of ginseng extract, 5-15 parts by weight of gardenia extract, 5-15 parts by weight of licorice extract, 5 to 15 parts by weight, health extract 1 to 10 parts by weight, and peppermint extract 1 to 10 parts by weight.
당귀 추출물 15 중량부, 백작약 추출물 15 중량부, 백출 추출물 15 중량부, 복령 추출물 15 중량부, 치자 추출물 10 중량부, 감초 추출물 10 중량부, 길경 추출물 10 중량부, 건강 추출물 5 중량부 및 박하 추출물 5 중량부인 것을 특징으로 하는 골질환 예방 또는 치료용 약학적 조성물.
2. The composition of claim 1,
15 parts by weight of Angelica keiskei koidz. Extract, 15 parts by weight of Baekjang extract, 15 parts by weight of extract, 15 parts by weight of ginseng extract, 10 parts by weight of gardenia extract, 10 parts by weight of licorice extract, 10 parts by weight of Gakyung extract, 5 parts by weight of health extract, 5 < / RTI > parts by weight of the composition.
The pharmaceutical composition for preventing or treating bone diseases according to claim 1, wherein the extract is extracted with water, a C 1 to C 2 lower alcohol or a mixed solvent thereof.
The pharmaceutical composition for preventing or treating bone diseases according to claim 1, wherein the composition increases bone density and bone content.
Health food for prevention or improvement of bone diseases, containing Angelica gigas, Veterinary medicine, Baekyoung, Byeongryeong, Gardenia, Licorice, Gakyung, Health and peppermint extract as active ingredients.
당귀 추출물 10 ~ 20 중량부, 백작약 추출물 10 ~ 20 중량부, 백출 추출물 10 ~ 20 중량부, 복령 추출물 10 ~ 20 중량부, 치자 추출물 5 ~ 15 중량부, 감초 추출물 5 ~ 15 중량부, 길경 추출물 5 ~ 15 중량부, 건강 추출물 1 ~ 10 중량부 및 박하 추출물 1 ~ 10 중량부인 것을 특징으로 하는 골질환 예방 또는 개선용 건강식품.
10. The method according to claim 9,
10-20 parts by weight of Angelica gigantosa extract, 10-20 parts by weight of Baekjang extract, 10-20 parts by weight of extract, 10-20 parts by weight of ginseng extract, 5-15 parts by weight of gardenia extract, 5-15 parts by weight of licorice extract, 5 to 15 parts by weight, health extract 1 to 10 parts by weight and peppermint extract 1 to 10 parts by weight.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170022634A KR101864719B1 (en) | 2017-02-21 | 2017-02-21 | Composition for prevention and treatment of osteoporosis comprising the extract of medicinal herb mixture |
| CN201810151501.8A CN108452033B (en) | 2017-02-21 | 2018-02-14 | Composition containing mixed Chinese medicinal material extract for preventing and treating bone diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170022634A KR101864719B1 (en) | 2017-02-21 | 2017-02-21 | Composition for prevention and treatment of osteoporosis comprising the extract of medicinal herb mixture |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR101864719B1 true KR101864719B1 (en) | 2018-06-05 |
Family
ID=62635553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170022634A KR101864719B1 (en) | 2017-02-21 | 2017-02-21 | Composition for prevention and treatment of osteoporosis comprising the extract of medicinal herb mixture |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR101864719B1 (en) |
| CN (1) | CN108452033B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102255000B1 (en) * | 2020-04-29 | 2021-05-24 | 한국 한의학 연구원 | Composition for preventing, improving or treating bone disease comprising Mentha arvensis extract as effective component |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109260430A (en) * | 2018-10-19 | 2019-01-25 | 江苏万医堂生物科技有限公司 | A kind of liquid medicine and preparation method thereof with activating microcirculation and removing stasis medicinal remove rheumatism osteopathy function |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0994452A (en) | 1995-10-03 | 1997-04-08 | Teika Corp | Dispersant |
| KR19990085303A (en) | 1998-05-15 | 1999-12-06 | 성재갑 | Skin whitening material |
| KR20050072625A (en) | 2004-01-07 | 2005-07-12 | 학교법인 동의학원 | A composition for prevention and improvement of osteoporosis |
| KR20130070870A (en) * | 2011-12-20 | 2013-06-28 | 가천대학교 산학협력단 | Pharmaceutical composition comprising extract of dsx showing an inhibitory effect of bone formation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105688119A (en) * | 2014-11-25 | 2016-06-22 | 孙振坤 | Chinese patent medicine used for treating bone necrosis |
| CN104873631B (en) * | 2015-04-28 | 2018-07-13 | 即墨爱心医院 | It is a kind of to be used to treat Chinese medicine composition of osteopathy and preparation method thereof and bone disease treatment instrument |
-
2017
- 2017-02-21 KR KR1020170022634A patent/KR101864719B1/en active IP Right Grant
-
2018
- 2018-02-14 CN CN201810151501.8A patent/CN108452033B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0994452A (en) | 1995-10-03 | 1997-04-08 | Teika Corp | Dispersant |
| KR19990085303A (en) | 1998-05-15 | 1999-12-06 | 성재갑 | Skin whitening material |
| KR20050072625A (en) | 2004-01-07 | 2005-07-12 | 학교법인 동의학원 | A composition for prevention and improvement of osteoporosis |
| KR20130070870A (en) * | 2011-12-20 | 2013-06-28 | 가천대학교 산학협력단 | Pharmaceutical composition comprising extract of dsx showing an inhibitory effect of bone formation |
Non-Patent Citations (12)
| Title |
|---|
| Akhani SP et el., Antidiabetic activity of Zingiber officinale in streptozotocin-induced type I diabetic rats, J. Pharm. Pharmacol, 56(1), pp.101-105, 2004 |
| Altern. Med. Rev., 6(5), pp495-499, 2001 |
| Goto H et al., Phytother. Res,13(6), pp526-528, 1999 |
| Ishida H et al.,Chem. Pharm. Bull, 35(2), pp849-852, 1987 |
| Lin HC et al., Planta Med , 65, pp595-599, 1999 |
| Ohsugi M et al., J. Ethnopharmacol., 67, pp111-119, 1999 |
| Vishwakarma SL et el., Anxiolytic and antiemetic activity of Zingiber officinale, Phytother. Res., 16(7), pp.621-626, 2002 |
| Yang HO et al., Fitoterapia, 75(1), pp45-49, 2004 |
| Yang J et al., Zhong Yao Cai, 23(2), pp95-97, 2000 |
| Zhang GQ et al., Acta Pharmacol. Sin., 24(12), pp1248-1252, 2003 |
| 김미향 저, Korean J. Oriental Physiology & Pathology, 2008, 22(1), 183∼188 (2008)* * |
| 박찬수 ( Chan Soo Park ), 손영주 ( Young Joo Sohn ) 대한한방부인과학회지 21권 1호 2008년 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102255000B1 (en) * | 2020-04-29 | 2021-05-24 | 한국 한의학 연구원 | Composition for preventing, improving or treating bone disease comprising Mentha arvensis extract as effective component |
| WO2021221457A1 (en) * | 2020-04-29 | 2021-11-04 | 한국 한의학 연구원 | Composition for preventing, alleviating, or treating bone diseases, containing mentha arvensis extract as active ingredient |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108452033B (en) | 2021-07-16 |
| CN108452033A (en) | 2018-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101346244B1 (en) | Composition for preventing or relieving alcohol-induced hangover comprising medicinal herbs | |
| KR20080050794A (en) | Composition comprising complex crude drug extract (mst) for preventing and treating obesity | |
| KR100980819B1 (en) | The composition comprising complex herbal extract as an active ingredient and the preparation method thereof | |
| CN113288925A (en) | Traditional Chinese medicine composition for preventing and treating gout | |
| KR100854442B1 (en) | Composition comprising an extract of Nelumbinis Folium or herb complex for preventing or treating hyperlipidemia and arteriosclerosis | |
| KR101864719B1 (en) | Composition for prevention and treatment of osteoporosis comprising the extract of medicinal herb mixture | |
| KR100703180B1 (en) | A pharmaceutical composition comprising the extract of herb mixture for treating or preventing osteoporosis disease | |
| CN102784366B (en) | Medical composition with function of decanting and protecting liver | |
| CN104524146A (en) | Traditional Chinese medicine composition for prevention and adjuvant treatment of hypertensive, hyperlipidemia and hyperglycemia and application of traditional Chinese medicine composition | |
| KR100514132B1 (en) | Composition and kit for losing body weight | |
| KR101479096B1 (en) | Health functional food comprising extracts of herbal mixture for preventing or improving edema of delivered or pregnant woman | |
| KR100522176B1 (en) | Composition for improving male sexual function | |
| KR101421347B1 (en) | A method for preparing the essential oil fraction showing potent anti-obesity and inhibiting activity on fatty liver from Angelica gigas Nakai and the composition comprising the same the prevention or treatment of obesity and fatty liver | |
| KR101293835B1 (en) | Composition comprising the combined extract of Astragalus membranaceus Bunge and Plantago asiatica for preventing and treating obesity | |
| KR101781432B1 (en) | The composition for assisting of hyperlipidemia using medicinal plants and Gyeongokgo thereby | |
| KR101693573B1 (en) | A pharmaceutical composition for preventing or treating climacteric symptoms, and method of preparing the same | |
| CN103933472A (en) | Traditional Chinese medicine composition for resisting liver cancer and lung cancer | |
| KR102217732B1 (en) | Composition for preventing and improving the development of premature pseudo-breast | |
| KR20110097220A (en) | Composition for the prevention and treatment of lipid-related cardiovascular disease or obesity containing the extracts of dictamnus dasycarpus as active ingredient | |
| CN112057536B (en) | Traditional Chinese medicine composition for preventing or/and treating dyslipidemia and application thereof | |
| CN112057535B (en) | Preparation method of traditional Chinese medicine composition for preventing or/and treating dyslipidemia | |
| CN112089783B (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity | |
| KR20060030575A (en) | Pharmaceutical composition comprising the complex crude drug extract for preventing and treating hyperthyroidism | |
| KR101241338B1 (en) | Composition for the prevention and treatment of lipid-related cardiovascular disease or obesity containing extracts of Polygonum aviculare as active ingredient | |
| CN116059289A (en) | Kelp composition for regulating intestinal flora and helping to maintain blood fat health and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |